Print

Additional Data From Pfizer Inc. (PFE)'s Prevnar 13(R) Clinical Trials in Adults 50 Years and Older to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America  
10/21/2011 11:36:30 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the pending regulatory applications for the use of Prevnar 13 in adults 50 years and older to help prevent pneumococcal disease.
//-->